Danish Software Stock News

Ørsted (CPSE:ORSTED) closed out FY 2025 with Q4 revenue of DKK23.1b and a basic EPS loss of DKK1.77, while trailing twelve month EPS sat at DKK1.95 on revenue of DKK73.2b. Over recent periods the company has seen quarterly revenue range from DKK12.3b to DKK23.1b and EPS swing from a profit of DKK10.57 in Q1 2025 to losses in Q3 and Q4. Investors are watching how consistently that full year profitability holds up. With trailing net income of DKK1.7b against those sizable top line figures, the...

One of the biggest stories of last week was how Novo Nordisk A/S ( CPH:NOVO B ) shares plunged 20% in the week since...

It's been a sad week for H. Lundbeck A/S ( CPH:HLUN B ), who've watched their investment drop 11% to kr.37.46 in the...

There's been a major selloff in ChemoMetec A/S ( CPH:CHEMM ) shares in the week since it released its interim report...

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...

Danske Bank (CPSE:DANSKE) has wrapped up FY 2025 with fourth quarter revenue of DKK 15.2b and basic EPS of DKK 7.73, supported by trailing twelve month revenue of DKK 56.5b and EPS of DKK 27.94 that frame the latest print in a wider earnings run rate. That backdrop of steady headline revenue and EPS trends sets up a results season where the key question for you is how far the current profitability mix, including modestly softer margins, aligns with the rewards and risks already on your...

Pandora (CPSE:PNDORA) is shifting its core jewelry offering from silver based products to platinum plated pieces, aiming to reduce exposure to swings in silver prices. The company is pausing its share buyback program as it reallocates capital toward this product overhaul. Pandora is also reshaping its leadership team, including the appointment of a new chief product officer, to support the transition. Pandora, known globally for its charm bracelets and accessible jewelry, is moving its...

Recent share performance and business snapshot Ørsted (CPSE:ORSTED) has recently attracted attention after a period of mixed share performance, with the stock showing gains over the past week, month and past 3 months despite weaker longer term returns. The company operates across three main segments: Offshore, Onshore and Bioenergy & Other. It develops and runs wind, solar, energy storage, renewable hydrogen and bioenergy assets in Europe, the United States and the Asia Pacific region. See...

Demant (CPSE:DEMANT) has drawn fresh attention after its 2025 results combined softer net income with a cautious 2026 outlook and a plan to cut 700 jobs, prompting a sharp share price reaction. See our latest analysis for Demant. The latest earnings announcement, cautious 2026 guidance and cost saving plan have come on top of a weak run for the shares, with a 7 day share price return of 14.61% decline and a 1 year total shareholder return of 28.98% decline pointing to fading momentum. If...

Carlsberg (CPSE:CARL B) has posted its FY 2025 numbers with second half revenue of DKK 43.2b, basic EPS of DKK 18.10 and net income of DKK 2,393m, while the first half delivered revenue of DKK 45.9b, basic EPS of DKK 26.95 and net income of DKK 3,562m. The company has seen first half revenue move from DKK 38.8b in 2024 with basic EPS of DKK 28.08 and net income of DKK 3,739m to DKK 45.9b in 2025, which sets the scene for investors to focus on how current margins and expectations for future...

If you are wondering whether Novo Nordisk’s share price now reflects fair value or an opportunity, you are not alone. This article is built to help you size that up clearly. The stock last closed at DKK 280.65, with returns of 24.2% decline over 7 days, 22.9% decline over 30 days, 15.0% decline year to date, 54.5% decline over 1 year, and 38.9% decline over 3 years, while still showing a 36.1% gain over 5 years. Recent news coverage has focused heavily on Novo Nordisk’s role in diabetes and...

If you are wondering whether Vestas Wind Systems is still attractively priced after its recent run, this article will help you unpack what the current share price might be implying about future expectations. The stock trades at DKK 176.4 after a 6.1% decline over the last 7 days and a 5.8% decline over the last 30 days, although the 1 year return sits at 65.9%. These moves come as Vestas continues to be a focal point in global wind power discussions, with investors paying close attention to...

Wondering whether Carlsberg’s current share price really reflects what you are getting as an investor? This article walks through the numbers so you can judge the value for yourself. Carlsberg’s shares last closed at DKK 939.0, with returns of 10.2% over 7 days, 13.5% over 30 days, 13.7% year to date, 22.2% over 1 year, 5.9% over 3 years and 11.7% over 5 years. This provides useful context before thinking about what the stock might be worth. Recent coverage around Carlsberg has focused on...

Embla Medical hf (CPSE:EMBLA) has wrapped up FY 2025 with fourth quarter revenue of US$256.7 million and basic EPS of US$0.058, on trailing twelve month revenue of US$928.7 million and EPS of US$0.196 that frame the latest print. Over recent periods the company has seen revenue move from US$224.8 million and EPS of roughly US$0.044 in Q4 2024 to US$256.7 million and EPS of US$0.058 in Q4 2025, with trailing net income rising from US$68.3 million to US$83.3 million. This sets up a story where...

Demant A/S has released its full-year 2025 results, reporting sales of DKK 22,971 million, up from DKK 22,419 million a year earlier, while net income fell to DKK 1,545 million and basic earnings per share from continuing operations declined to DKK 11.2. The combination of higher sales but lower net income and earnings per share highlights shifting cost, margin or mix effects that may reshape how investors view Demant’s underlying earnings quality. We’ll now examine how Demant’s higher sales...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

What are the early trends we should look for to identify a stock that could multiply in value over the long term...

ISS (CPSE:ISS) has secured a full Integrated Facility Services contract with a major life sciences and pharmaceutical client in Switzerland, valued at nearly DKK 300 million annually across four locations. See our latest analysis for ISS. The contract win comes as ISS shares trade at DKK245.2, with a 30 day share price return of 13.73% and a 90 day gain of 19.49%. The 1 year total shareholder return of 81.37% and 5 year total shareholder return of 142.04% point to strong momentum that recent...

Danske Bank has completed its DKK 5,000,000,000 share buy-back programme, repurchasing 19,179,623 shares that are expected to be cancelled subject to shareholder approval at the March 26, 2026 annual general meeting. This move underscores a capital position that allows meaningful cash returns to investors and signals management’s confidence in the bank’s current trajectory. We’ll now examine how the completed DKK 5,000,000,000 buy-back and planned share cancellation shape Danske Bank’s...

NKT announced that it has signed final contracts under its framework agreement with SSEN Transmission to deliver 525 kV HVDC on- and offshore power cable systems for the Western Isles and Spittal to Peterhead links in Scotland, adding about €2.00 billion to its high-voltage order backlog. Beyond expanding NKT’s backlog, the projects highlight the company’s role in enabling large-scale grid reinforcement for Great Britain’s electricity transmission network. Next, we’ll examine how securing...

As the eurozone economy continues its modest recovery, with consumer and business confidence on the rise despite mixed performances in major stock indexes, investors are keenly observing growth companies that demonstrate strong insider ownership. In this context, stocks with high insider ownership can be particularly appealing as they often reflect a management team’s confidence in their company’s long-term potential and alignment with shareholder interests.

Recently, Ambu’s CEO Britt Meelby Jensen joined a Danish life science delegation to China, presenting a new Chinese-made endoscope as part of efforts to deepen cooperation and diversify the company’s global value chain away from a more difficult US market. This move highlights how Ambu is reconfiguring its manufacturing and market exposure to tap Chinese healthcare demand while reducing reliance on a single geography. We’ll now examine how Ambu’s increased focus on Chinese manufacturing and...

Key Insights The considerable ownership by individual investors in TORM indicates that they collectively have a greater...

INFUSE study data puts Vyepti in focus for Lundbeck investors H. Lundbeck (CPSE:HLUN B) has drawn investor attention after presenting six month real world INFUSE study data on its migraine treatment Vyepti at the 2026 Headache Cooperative of the Pacific conference. See our latest analysis for H. Lundbeck. The INFUSE update lands after a mixed stretch for the shares, with a 1-day share price return of 1.06% to DKK42.12 contrasting with weaker 7-day, 90-day and 1-year total shareholder return...